Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Matthew M. Ravn et al.|Molecular Cancer Therapeutics|2022Cited by 35
133 CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicityJonathan Terrett, Demetrios Kalaitzidis, Brigid McEwan et al.|Regular and Young Investigator Award Abstracts|2021Cited by 0
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0